Abstract
Breast cancer management has become increasingly complex, requiring the integration of data not only from the patients history and imaging modalities but also from specific tumor biomarkers and gene expression. Targeted and biologic therapies in breast cancer continue to evolve rapidly. The field of molecular targeted therapy has emerged. Its ultimate goal is to personalize and simplify treatment as well as minimize toxicity. This review aims at highlighting the current state-of-the-art in novel molecular targeted therapies for breast cancer based on multi-targeted small molecule tyrosine kinase inhibitors (TKI). The first two agents in this group entering clinic, Lapatinib (GW572016; Tykerb ®) and SUNITINIB (SU11248; Sutent®) are discussed. This review article also includes relevant patents.
Keywords: Multitargeted, small molecule, tyrosine kinase inhibitors, breast cancer
Recent Patents on Anti-Cancer Drug Discovery
Title: Molecularly Targeted Therapy in Breast Cancer: The New Generation
Volume: 3 Issue: 2
Author(s): Zeina A. Nahleh
Affiliation:
Keywords: Multitargeted, small molecule, tyrosine kinase inhibitors, breast cancer
Abstract: Breast cancer management has become increasingly complex, requiring the integration of data not only from the patients history and imaging modalities but also from specific tumor biomarkers and gene expression. Targeted and biologic therapies in breast cancer continue to evolve rapidly. The field of molecular targeted therapy has emerged. Its ultimate goal is to personalize and simplify treatment as well as minimize toxicity. This review aims at highlighting the current state-of-the-art in novel molecular targeted therapies for breast cancer based on multi-targeted small molecule tyrosine kinase inhibitors (TKI). The first two agents in this group entering clinic, Lapatinib (GW572016; Tykerb ®) and SUNITINIB (SU11248; Sutent®) are discussed. This review article also includes relevant patents.
Export Options
About this article
Cite this article as:
Nahleh A. Zeina, Molecularly Targeted Therapy in Breast Cancer: The New Generation, Recent Patents on Anti-Cancer Drug Discovery 2008; 3 (2) . https://dx.doi.org/10.2174/157489208784638794
DOI https://dx.doi.org/10.2174/157489208784638794 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Flavonoids: Prospective Drug Candidates
Mini-Reviews in Medicinal Chemistry FbD Supported Development and In Vitro Evaluation of Carbomer based Resveratrol Loaded Topical Antipsoriatic Nanoemulgel for its Targeted Skin Delivery
Pharmaceutical Nanotechnology Licochalcone B Arrests Cell Cycle Progression and Induces Apoptosis in Human Breast Cancer MCF-7 Cells
Recent Patents on Anti-Cancer Drug Discovery Editorial
Current Medical Imaging Glutathione-Triggered Drug Release from Nanostructures
Current Topics in Medicinal Chemistry A Comprehensive Overview of the Synthesis of Tetrahydrocarbazoles and its Biological Properties
Mini-Reviews in Organic Chemistry Challenges and Solutions in the Development of Genomic Biomarker Panels: A Systematic Phased Approach
Current Genomics Decoding the Inter-Relationship between Sleep Disorders and Alzheimer’s Disease Pathogenesis
CNS & Neurological Disorders - Drug Targets BRCA2 Dysfunction Promotes Malignant Transformation of Pancreatic Intraepithelial Neoplasia
Anti-Cancer Agents in Medicinal Chemistry CD26: A Multi-Purpose Pharmacological Target
Current Clinical Pharmacology Iron Deficiency: The Hidden Miscreant in Inflammatory Bowel Disease
Current Drug Targets Cordycepin Affects Multiple Apoptotic Pathways to Mediate Hepatocellular Carcinoma Cell Death
Anti-Cancer Agents in Medicinal Chemistry Cutting the Limits of Aminobisphosphonates: New Strategies for the Potentiation of their Anti-Tumour Effects
Current Cancer Drug Targets The Upshot of PI3K Inhibitors as Anticancer Arsenal: A Short Review
Current Bioactive Compounds Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer
Current Drug Targets Understanding and Applying Personalized Therapeutics at Systems Level:Role for Translational Bioinformatics
Current Pharmacogenomics and Personalized Medicine Therapeutic Use of Vitamin D and its Analogues in Autoimmunity
Recent Patents on Inflammation & Allergy Drug Discovery Pathogenesis, Experimental Models and Contemporary Pharmacotherapy of Irritable Bowel Syndrome: Story About the Brain-Gut Axis
Current Neuropharmacology Interactions of Phenothiazines with Lipid Bilayer and their Role in Multidrug Resistance Reversal
Current Drug Targets Potential Health Benefits of a Pomegranate Extract, Rich in Phenolic Compounds, in Intestinal Inflammation
Current Nutrition & Food Science